Rigel Pharmaceuticals Up Over 36%, on Track for Highest Close Since May 2022 -- Data Talk

Dow Jones11-09

Rigel Pharmaceuticals, Inc. (RIGL) is currently at $21.10, up $5.66 or 36.66%

 

--Would be highest close since May 19, 2022, when it closed at $21.20

--On pace for largest percent increase since May 17, 2023, when it rose 41.09%

--Currently up five of the past six days

--Currently up four consecutive days; up 49.96% over this period

--Longest winning streak since July 16, 2024, when it rose for eight straight trading days

--Best four day stretch since the four days ending May 17, 2023, when it rose 56.9%

--Up 54.81% month-to-date

--Up 45.52% year-to-date; on pace for best year since 2020, when it rose 63.55%

--Down 98.03% from its all-time closing high of $1068.75 on Jan. 3, 2001

--Up 157.98% from 52 weeks ago (Nov. 10, 2023), when it closed at $8.18

--Would be a new 52-week closing high

--Up 172.96% from its 52-week closing low of $7.73 on July 3, 2024

--Traded as high as $21.20; highest intraday level since May 20, 2022, when it hit $21.85

--Up 37.31% at today's intraday high; largest intraday percent increase since June 27, 2024, when it rose as much as 37.81%

 

All data as of 1:46:26 PM ET

 

Source: Dow Jones Market Data, FactSet

 

(END) Dow Jones Newswires

November 08, 2024 13:50 ET (18:50 GMT)

Copyright (c) 2024 Dow Jones & Company, Inc.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment